Expression of some molecular and biological markers in esophageal tumors of various stages and grades

Objectives: immunohistochemical study of the expression of molecular and biological markers (p53, bcl-2 and ki-67) in esophageal tumors of various stages and grades, and evaluation of the markers in the disease prognosis. Material and methods: the study included 30 patients of a retrospective group with stage II-III squamous cell carcinoma of the esophagus. Immunohistochemical study of paraffi n sections was performed using primary mouse monoclonal antibodies against p53, bcl-2 and ki67, and Reveal Polyvalent HRP-DAB Detection System. Results: diff erences in the rates and expression of molecular and biological markers (p53, bcl-2 and ki-67), controlling apoptosis and proliferation, depended on the tumor stage and grade. Conclusions: fdvanced cancer of the esophagus demonstrated an increase in rates and expression of p53+ and ki-67, as well as in the proliferative activity of tumor cells. Bcl-2 expression was more frequent and intensive in stage II tumors, compared to stage III. Esophageal tumors of higher grades were characterized with higher rates and expression of p53 and ki-67, and conversely for the bcl-2 expression. Th e revealed diff erences can be used in the disease prognosis.

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GlOBOCAN 2012: Estimated Cancer Icidence Mortality and Prevalence Worldwide in 2012. Word Health Organization, International Agency for Researchon Cancer. International Agencyfor Researchon Cancer. 2012.

2. Mironchev AO, Kagan II, Mironchev OV, Samojlov PV. Morphological changes of the esophagus in adenocarcinoma and squamous cell carcinoma. EHksperimental’naya i klinicheskaya gastroehnterologiya. 2014;111(11):61-64. (in Russ.)

3. Ter-Ovanesov MD, Levickij AV. Advances in clinical Oncology tumors of the gastrointestinal tract in 2010: steps forward or reminiscences of the past? Prakticheskaya onkologiya. 2011;12(1):17-25. (in Russ.)

4. Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Karashima R, et al. Р53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma. Med Oncol. 2013;30(4):728. doi: 10.1007/s12032-013-0728-z

5. Madani K, Zhao R, Lim HJ, Casson AG. Prognostic value of p53 mutations in oesophageal adenocarcinoma: fi nal results of a 15-year prospective study. Eur J Cardiothorac Surg. 2010;37(6):1427–1432. doi: 10.1016/j.ejcts.2009.12.018

6. Wang L, Yu X, Li J, Zhang Z, Hou J, Li F. Prognostic signifi cance of p53 expression in patients with esophageal cancer: a meta-analysis BMC. Cancer. 2016;16:373. doi: 10.1186/s12885-016-2427-6

7. Wei W, Wang Y, Yu X, Ye L, Jiang Y, Cheng Y. Expression of TP53, BCL-2, and VEGFA Genes in Esophagus Carcinoma and its Biological Signifi cance. Med SciMonit. 2015;21:3016– 3022. doi: 10.12659/MSM.894640

8. Petrov SV, Rajhlin NT. Manual on immunohistochemical diagnostics of human tumors. Kazan’; 2012.

9. Borovikov VP. STATISTICA: the art of data analysis on the computer. For professionals. SPb.: Piter; 2001.